14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
EHTH vs EBS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas EBS carries 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin).
Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EHTH vs EBS. Trailing 12-month operating profitability (EHTH 11.9% vs EBS 5.8%) and valuation multiples (EHTH 0.2x vs EBS 20.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $297.7M market capitalization and 5.8% operating margin.
OpEx & R&D Reinvestment37.6% of Rev ($244M)
90D Engineering Disclosures0 Published
Investor FAQ EHTH vs EBS Key Questions & Quantitative Answers
As of Nov 17, 2026, Emergent Biosolutions, Inc. (EBS) is the stronger overall head-to-head candidate over eHealth, Inc. (EHTH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). EHTH carries a Unified Composite Score of 40.8/100 (SELL) at $0.35 (0.2x Forward P/E, 11.9% operating margin), whereas EBS carries 54.3/100 (HOLD) at $5.63 (20.0x Forward P/E, 5.8% operating margin). Technical & Structure Timing Caution: EHTH is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.9); meanwhile EBS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 37.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EBS leads the Growth & Scale pillar: EHTH posts -60.5% YoY revenue growth and -17.6% YoY earnings growth on $469M TTM revenue (100.0% gross margin, 11.9% operating margin), compared with EBS at -52.4% YoY revenue growth and -93.8% YoY earnings growth on $649M TTM revenue (43.4% gross margin, 5.8% operating margin). On trailing 12-month operating scale, EHTH generates $469M in USD-normalized revenue versus $649M for EBS. In operating R&D and SG&A reinvestment, EHTH deploys N/A (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($244M) (0 disclosures) for EBS.
EHTH screens cheaper on headline valuation multiples. EHTH trades at 0.2x Forward P/E, 0.2x Trailing P/E, 0.72x PEG, and N/M EV/Revenue (12.4% EBITDA margin), whereas EBS trades at 20.0x Forward P/E, 20.0x Trailing P/E, 0.38x PEG, and 1.0x EV/Revenue (29.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EHTH (2.6% ROE) versus EBS (-58.2% ROE) capital efficiency.
In options market volatility and institutional positioning, EHTH carries 128.7% implied volatility (56th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.61β · 117% Vol realized risk). By comparison, EBS carries 73.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.81β · 49% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.